Imbruvica Market: How the BTK Inhibitor Pioneer Is Building a USD...

blog ekledi Botanik

2026-06-18 10:22:45

Imbruvica Market: How the BTK Inhibitor Pioneer Is Building a USD 15 Billion Franchise by 2035

The global Imbruvica Market represents one of oncology's most commercially consequential single-drug stories of the past decade. Valued at USD 6.14 billion in 2024 and projected to reach USD 15 billion by 2035 at a CAGR of 8.4%, Imbruvica (ibrutinib) — the first approved Bruton's tyrosine kinase (BTK) inhibitor — has transformed the treatment landscape for B-cell malignancies and...

0 Yorumlar 0 Paylaşımlar 11 Görüntülenme 0 İncelemeler